Skip to content

Novel Medical Device for Pharmacological Therapy

A Pilot Study of a Novel Medical Device for Pharmacological Therapy: The SecHold Device

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06938750
Acronym
Sechold
Enrollment
262
Registered
2025-04-22
Start date
2023-01-20
Completion date
2026-09-20
Last updated
2025-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter Infection, Catheter Malfunction, Innovative Procedures, Nurse, Nurse Based Care Management, Therapeutic Drug Management, Vascular Access, Vascular Access Complication, Vascular Access Complications

Keywords

VASCULAR ACCESS, CATHETER, THERAPY, COMPLICATION, DEVICE, CENTRAL VASCULAR ACCESS

Brief summary

Background: Different co-creation methods were used to design and prototype a new fixative device for multiple intravenous therapies with the ability to control and identify the pharmacological therapy administered to a patient. Objectives: To validate a newly created device for the reduction of complications related to the use of intravenous therapy Methods: A multidisciplinary team composed of eight professionals specializing in the field of critical care and an engineering professional in industrial design was responsible for collecting, evaluating, and materializing the ideas and needs arising from clinical practice in a device that met the standards of the same.

Interventions

DEVICESECHOLD DEVICE

PLACEMENT OF A MULTIPLE THERAPY GRIPPING DEVICE TO FIX THE DRIPPER SYSTEMS ALONG ITS PATH TO SOME SURFACE OR SPACE, AVOIDING IT TO REMAIN IN THE AIR, WITHOUT MARKING OR LABELING AND FAVORING ITS ORGANIZATION. SECHOLD is a vascular access fixation device designed for critical clinical environments such as ICU and operating rooms. It allows the simultaneous connection of 3-6 parenteral therapies to the same vascular access, ensuring clear and protocolized identification of each drug by means of labels with name, concentration and infusion range, in addition to a universal color code. This reduces the risk of drug administration errors and facilitates optimal visualization of essential information. SECHOLD also organizes infusion systems connected to the same vascular access, preventing knots and pulls that can compromise catheter integrity in case of accidental infusion bag drops.

Sponsors

Fundacion Miguel Servet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

A clinical trial was carried out in an intensive care unit of the University Hospital of Navarra, a tertiary hospital reference center in intensive care in Navarra, in the north of Spain; where the use and clinical validation process of a newly created device registered by European patent as a utility model was implemented. This study was made over a period of 6 months, from June 2021 to December of the same year; after internal authorization from the center where the clinical validation process has been carried out and from the local ethics committee (pyto2019/47).

Eligibility

Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients admitted to the intensive care unit * patients with authorization to take part in the study

Exclusion criteria

* Patients with pre-existing medical conditions: Patients with diseases affecting coagulation, such as hemophilia or thrombocytopathies, could be excluded. * Active infection patients: Any patient with vascular access site infections or systemic infections may be excluded to avoid complications. * Inability to give informed consent: Patients who are unable to understand or consent to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
To reduce the risk of complications associated with the number of pharmacological errors.day 1, day 7, day 14, at 6 months after placement and start of the studyRecognize the number of pharmacological errors (DRUG INTERACTION, WRONG DRUG, WRONG DOSAGE, WRONG SPEED) that have occurred
To reduce complications associated with accidental catheter withdrawals.day 1, day 7, day 14, at 6 months after placement and start of the studyNumber of complications associated with accidental catheter withdrawals during the study period

Secondary

MeasureTime frameDescription
Reduce complications associated with venous catheter placement and maintenance (thrombosis, phlebitis, catheter obstruction).day 1, day 7, day 14, at 6 months after placement and start of the studyNumber of complications associated with venous catheter placement and maintenance (thrombosis, phlebitis, catheter obstruction)

Other

MeasureTime frameDescription
Improved satisfaction of healthcare professionals operating the device.day 1, day 7, day 14, at 6 months after placement and start of the studySatisfaction Questionnaire: A form used in the workplace with an overall satisfaction level will be used with a Liker scale of 1-10, with 1 being not at all satisfactory and 10 being maximum satisfaction.

Countries

Spain

Contacts

Primary Contactmarta M FERRAZ-TORRES, PHD
marta.ferraz.torres@navarra.es+34628813974

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026